Angiotensin II Receptor Blockade in Normotensive Subjects
- 1 March 1999
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Hypertension
- Vol. 33 (3) , 850-855
- https://doi.org/10.1161/01.hyp.33.3.850
Abstract
—Use of angiotensin (Ang) II AT 1 receptor antagonists for treatment of hypertension is rapidly increasing, yet direct comparisons of the relative efficacy of antagonists to block the renin-angiotensin system in humans are lacking. In this study, the Ang II receptor blockade induced by the recommended starting dose of 3 antagonists was evaluated in normotensive subjects in a double-blind, placebo-controlled, randomized, 4-way crossover study. At 1-week intervals, 12 subjects received a single dose of losartan (50 mg), valsartan (80 mg), irbesartan (150 mg), or placebo. Blockade of the renin-angiotensin system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous Ang II, in vitro Ang II receptor assay, and reactive changes in plasma Ang II levels. At 4 hours, losartan blocked 43% of the Ang II–induced systolic blood pressure increase; valsartan, 51%; and irbesartan, 88% ( P <0.01 between drugs). The effect of each drug declined with time. At 24 hours, a residual effect was found with all 3 drugs, but at 30 hours, only irbesartan induced a marked, significant blockade versus placebo. Similar results were obtained when Ang II receptor blockade was assessed with an in vitro receptor assay and by the reactive rise in plasma Ang II levels. This study thus demonstrates that the first administration of the recommended starting dose of irbesartan induces a greater and longer lasting Ang II receptor blockade than that of valsartan and losartan in normotensive subjects.Keywords
This publication has 12 references indexed in Scilit:
- Angiotensin II antagonism and plasma radioreceptor‐kinetics of candesartan in manBritish Journal of Clinical Pharmacology, 1998
- Plasma bradykinin in angio-oedemaThe Lancet, 1998
- An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartanClinical Therapeutics, 1998
- Angiotensin Converting Enzyme Inhibition Corrects Na+/H+ Exchanger Overactivity in Essential HypertensionAmerican Journal of Hypertension, 1997
- Valsartan: Preclinical and Clinical Profile of an Antihypertensive Angiotensin‐II AntagonistCardiovascular Drug Reviews, 1995
- Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjectsEuropean Journal of Clinical Pharmacology, 1994
- Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1‐receptor subtypeBritish Journal of Pharmacology, 1993
- Cough and Angioneurotic Edema Associated with Angiotensin-Converting Enzyme Inhibitor TherapyAnnals of Internal Medicine, 1992
- Determinants of angiotensin II generation during converting enzyme inhibition.Hypertension, 1990
- Angiotensin II measurement with high-affinity monoclonal antibodiesJournal Of Hypertension, 1988